Topics
Immunological Memory
Intestinal Microbiota & Immune System
Health Services Research
Drug Therapy Safety
Paediatric rheumatic diseases
Research
Pathophysiology of Rheumatic Inflammation
Epidemiology and Health Services Research
Systems Rheumatology
Technology platforms and service laboratories
Leibniz ScienceCampus Chronic Inflammation
Background and Partners
Campus discussions
Leibniz-Inflammation Lectures
1. Leibniz Summer School on Chronic Inflammation
Library
Publications
Networking
Science Awards
Career
Job Opportunities
Young Researchers
Graduate school
DRFZ Young Talents Fellowship
Welcome-Center
Latest News
News
Events
Seminars
DRFZ in the media
Subscribe to DRFZ NewsFlash
DRFZ vs SARS-CoV-2
Media Center
About Us
DRFZ at a glance
Patients and relatives
People at the DRFZ
DRFZ Structures
Donations
The DRFZ in the Leibniz Association
Public relations at the DRFZ
Equal opportunities
Animal Experiments at the DRFZ
Hasinger Lecture and Mitchison Prize
Guideline and Regulations
Language:
Deutsch
English
Menü
Topics
Topics
Immunological Memory
Intestinal Microbiota & Immune System
Health Services Research
Drug Therapy Safety
Paediatric rheumatic diseases
Research
Research
Pathophysiology of Rheumatic Inflammation
Epidemiology and Health Services Research
Systems Rheumatology
Technology platforms and service laboratories
Leibniz ScienceCampus Chronic Inflammation
Leibniz ScienceCampus Chronic Inflammation
Background and Partners
Campus discussions
Leibniz-Inflammation Lectures
1. Leibniz Summer School on Chronic Inflammation
Library
Publications
Networking
Science Awards
Career
Career
Job Opportunities
Young Researchers
Graduate school
DRFZ Young Talents Fellowship
Welcome-Center
Latest News
Latest News
News
Events
Seminars
DRFZ in the media
Subscribe to DRFZ NewsFlash
DRFZ vs SARS-CoV-2
Media Center
About Us
About Us
DRFZ at a glance
Patients and relatives
People at the DRFZ
DRFZ Structures
Donations
The DRFZ in the Leibniz Association
Public relations at the DRFZ
Equal opportunities
Animal Experiments at the DRFZ
Hasinger Lecture and Mitchison Prize
Guideline and Regulations
Home
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
|
19.04.2024
19. April 2024
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Print
Share
Also of interest
New mechanism of cortisone action deciphered
Sjögren-Tag 2024 am 6. April bei der Deutschen Rheuma-Liga Berlin
Sign up for the DRFZ NewsFlash
Sign up now
Deutsch
